Zydus Lifesciences - Excluding One-Offs, Earnings In-Line with Estimates
Zydus Lifesciences’ 4QFY22 revenue and adjusted net profit (Rs5,250mn) for inventory provisions were in-line with our estimates.
208 Views
Miss in 3Q; US / higher RM costs drag down earnings
Cadila Healthcare (CDH) delivered lower-than-expected 3QFY22 earnings, weighed by lower Domestic Formulation (DF) / US / EM sales and increased...
253 Views
Event Update - ZyCoV-D vaccine approved in increasingly competitive domestic market - BUY
trial of the vaccine on 28,000 volunteers, including 1400 subjects in the age group of 12-17 age group. With favorable and acceptable safety...
117 Views
Event Update - ZyCoV-D vaccine approved in increasingly competitive domestic market - BUY
trial of the vaccine on 28,000 volunteers, including 1400 subjects in the age group of 12-17 age group. With favorable and acceptable safety...
146 Views
Cadila Health Care: Outlook Promising with Strong Pipeline
Cadila Healthcare is India's leading vertically integrated pharmaceutical company. With its presence across the value chain, it manufactures...
147 Views